⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

October 1, 2024

Supplementary Figure 7 from Colorectal Cancer Recurrence Prediction Using a Tissue-Free Epigenomic Minimal Residual Disease Assay

Yoshiaki Nakamura Yuichiro Tsukada Nobuhisa Matsuhashi Tatsuro Murano Manabu Shiozawa Yusuke Takahashi Eiji Oki Masahiro Goto Yoshinori Kagawa Akiyoshi Kanazawa Takashi Ohta Akira Ouchi Hideaki Bando Hiroshi Uchigata Chiemi Notake Hiroaki Ikematsu Takayuki Yoshino

View at Publisher

Ask AI

Bookmark

Share

Abstract

Supplementary Figure 7. Risk of recurrence based on ctDNA detection 28 days post-surgery by pathologic stage.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Nakamura et al. (2024) studied this question.

synapsesocial.com/papers/68e56226e2b3180350efeec5 https://doi.org/10.1158/1078-0432.27142371

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure 8 from Colorectal Cancer Recurrence Prediction Using a Tissue-Free Epigenomic Minimal Residual Disease Assay2024
2Supplementary Figure 9 from Colorectal Cancer Recurrence Prediction Using a Tissue-Free Epigenomic Minimal Residual Disease Assay2024
3Supplementary Figure 4 from Colorectal Cancer Recurrence Prediction Using a Tissue-Free Epigenomic Minimal Residual Disease Assay2024
4Supplementary Figure 5 from Colorectal Cancer Recurrence Prediction Using a Tissue-Free Epigenomic Minimal Residual Disease Assay2024
5Supplementary Figure 1 from Colorectal Cancer Recurrence Prediction Using a Tissue-Free Epigenomic Minimal Residual Disease Assay2024

More related papers

Supplementary Figure 6 from Colorectal Cancer Recurrence Prediction Using a Tissue-Free Epigenomic Minimal Residual Disease Assay2024
Supplementary Figure 2 from Colorectal Cancer Recurrence Prediction Using a Tissue-Free Epigenomic Minimal Residual Disease Assay2024
Supplementary Figure S2 from Minimal Residual Disease using a Plasma-Only Circulating Tumor DNA Assay to Predict Recurrence of Metastatic Colorectal Cancer Following Curative Intent Treatment2024